Navigation Links
Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
Date:5/9/2008

CALGARY, May 9 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has begun patient enrolment in a clinical trial using intravenous administration of REOLYSIN(R) in combination with cyclophosphamide, a chemotherapeutic agent as well as immune modulator, in patients with advanced cancers. The Principal Investigators are Dr. James Spicer of King's College in London, Dr. Johann de Bono and Dr. Kevin Harrington of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, and Professor Hardev Pandha of the Royal Surrey County Hospital NHS Trust, Surrey and Mount Alvernia Hospitals.

"We are hopeful that this trial will provide more information on how we might improve the effectiveness of this promising new approach to treating cancer," said Dr. Spicer.

"In animal models, pretreatment with low-dose immune modulators has been shown to significantly enhance the antitumour activity of REOLYSIN(R)(ref.)," added Dr. Brad Thompson, President and CEO of Oncolytics. "This study will help confirm if this can also be achieved in humans. If it can, it could lead to exciting opportunities to expand the use of REOLYSIN(R) for cancer treatment."

The trial (REO 012) is an open-label, dose-escalating, non-randomized trial of REOLYSIN(R) given intravenously with escalating doses of cyclophosphamide. A standard dose of REOLYSIN(R) is administered intravenously over five consecutive days, while an intravenous dose of cyclophosphamide is administered three days before REOLYSIN(R) treatment and continues through the course of the treatment cycle. The total number of patients studied will depend on the number of dose levels tested, but it is anticipated to be approximately 30 patients.

Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours including pancreatic, lung and ovarian cancers that are refractory (have not responded) to sta
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Details of 2008 Annual Shareholder Meeting
2. Oncolytics Biotech Inc. Announces 2008 First Quarter Results
3. Oncolytics Biotech Inc. Announces Journal of Immunology Publication on Reovirus Activation of Dendritic Cells
4. Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma
5. Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Multiple Myeloma at AACR Annual Meeting
6. Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Pediatric Sarcomas at AACR Annual Meeting
7. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Paclitaxel and Carboplatin Trial
8. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial
9. Oncolytics Biotech Inc. Announces Issuance of 26th U.S. Patent
10. Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial
11. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... simple. From crop yields to disease risks, the biological ... "complex traits." Just as for heightthe textbook example of ... disease are shaped by multiple genetic and environmental influences, ... track down such genes, geneticists typically mate two individuals ... and a small mouseand then study their descendents, looking ...
(Date:9/19/2014)... YORK, September 18, 2014 Scientists at NYU Langone ... dramatically the efficiency of the process for turning adult ... well-known compounds, including vitamin C. Using the new technique ... cells obtained from adult skin cells by more than ... technique is efficient and reliable, and thus should generally ...
(Date:9/19/2014)... use light, rather than electricity, to move data ... efficiency is a growing concern as chips, transistor ... of optical circuits light emitters, modulators, and ... One promising light source for optical chips is ... when deposited as a single, atom-thick layer. Other ...
(Date:9/19/2014)... Jose, California (PRWEB) September 19, 2014 ... Nanotechnology and its potential to revolutionize the world ... agencies, multinational corporations and small start-ups. The early ... funded research projects largely due to the high ... investments. Government budgets earmarked for this evolving technology ...
Breaking Biology Technology:Want to link genes to complex traits? Start with more diversity 2NYU Langone scientists report reliable and highly efficient method for making stem cells 2NYU Langone scientists report reliable and highly efficient method for making stem cells 3Toward optical chips 2Toward optical chips 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4
... (Nasdaq: SGMO ) today reported second quarter 2011 ... quarter ended June 30, 2011, Sangamo reported a consolidated net ... a net loss of $3.9  million, or $0.09 per share, ... 2011, the company had cash, cash equivalents and marketable securities ...
... 2011 Once routinely discarded during the birth process, ... life-saving stem cells that can be collected and stored ... and vast medical potential, published data shows that three ... about cord blood banking. In connection with ...
... Calif., July 26, 2011 Synterra Energy, Inc. ... and assets for waste biomass conversion from Pacific ... Lion Bio-Energy (Toledo, Ohio).  With the merger, Synterra ... bio-refineries for the economic production of renewable fuels, ...
Cached Biology Technology:Sangamo BioSciences Reports Second Quarter 2011 Financial Results 2Sangamo BioSciences Reports Second Quarter 2011 Financial Results 3Sangamo BioSciences Reports Second Quarter 2011 Financial Results 4Sangamo BioSciences Reports Second Quarter 2011 Financial Results 5Sangamo BioSciences Reports Second Quarter 2011 Financial Results 6Sangamo BioSciences Reports Second Quarter 2011 Financial Results 7Parent's Guide to Cord Blood Foundation Launches Nation's First Searchable Map of U.S. Sites for Donating Umbilical Cord Blood 2Parent's Guide to Cord Blood Foundation Launches Nation's First Searchable Map of U.S. Sites for Donating Umbilical Cord Blood 3Synterra Energy Merges Key Technologies to Commercialize Next Generation Integrated Bio-refinery 2
(Date:9/19/2014)... of dinosaurs a newly discovered hadrosaur with ... named Rhinorex condrupus by paleontologists from ... lived in what is now Utah approximately 75 ... , Rhinorex, which translates roughly into "King Nose," ... other Cretaceous hadrosaurs like Parasaurolophus and Edmontosaurus. Hadrosaurs ...
(Date:9/19/2014)... from several Harvard University labs in collaboration with ... researchers with the intellectual raw materials needed to ... flexible materials. , With the advent of low-cost ... manufacturing technology, soft robotics is emerging as an ... rigid robot design, but working with pliable materials, ...
(Date:9/19/2014)... professor will study the unique bioelectric signaling system of ... people,s health. The OU researcher is working to ... produce the signals used to map the world around ... rate of 500-600 discharges a second throughout their lives. ... are extreme, but necessary for survival. , "There is ...
Breaking Biology News(10 mins):New hadrosaur noses into spotlight 2Soft robotics 'toolkit' features everything a robot-maker needs 2
... A team led by researchers at the University ... the "superbug" methicillin-resistant Staphylococcus aureus (MRSA) is ... is well known for causing difficult-to-treat and potentially fatal ... 1990s it has also been infecting otherwise healthy people ...
... study shows for the first time that episodes of ... the 2001-02 drought, greatly accelerated development of the mountain ... to chart the evolution of the current pine beetle ... beetle outbreak in the two primary host species, the ...
... a daily multivitamin, but little is known about a multivitamin,s ... Brigham and Women,s Hospital (BWH) finds that daily multivitamin use ... A similar BWH study, announced last month, found daily ... 8 percent. The cardiovascular disease findings will be presented ...
Cached Biology News:Superbug MRSA identified in US wastewater treatment plants 22001-2002 drought helped propel mountain pine beetle epidemic, says CU study 22001-2002 drought helped propel mountain pine beetle epidemic, says CU study 32001-2002 drought helped propel mountain pine beetle epidemic, says CU study 4Daily multivitamin use does not reduce cardiovascular disease risk in men 2
Vascular Endothelial Growth Factor C Class: Antibody Product Group: Angiogensis...
Tropomyosin 4 [Tm4]...
Phospho-MEF2A(Thr312)...
Mouse monoclonal [2A4] to Cytokeratin 8 + 18 + 19 ( Abpromise for all tested applications). Antigen: Cytokeratins isolated from cultured pig kidney epithelial cells. Entrez GeneID: 3856 S...
Biology Products: